Bionano Symposium Highlights Scaling Path for Optical Genome Mapping
Event summary
- Bionano Genomics hosted Symposium 2026, concluding February 27, 2026, with over 1,250 registrants and 35 speakers.
- Laboratories in the US, Canada, and Europe described scaling optical genome mapping (OGM) to process up to 3,000 samples per year with automation.
- Radboud University Medical Center has automated UHMW DNA isolation and labeling, currently processing 500 samples and targeting 3,000 annually.
- Bionano’s Ionic system enables purification of DNA and RNA from FFPE samples, potentially improving NGS assay performance.
- Dr. Adam Smith (Labcorp) indicated OGM adoption requires less than 1/8 of the initial investment compared to long-read sequencing for 1,000 samples.
The big picture
Bionano's Symposium highlights a shift towards scalable genomic analysis, particularly in hematologic malignancies and constitutional disorders. The emphasis on automation and integration with existing workflows suggests a move away from purely research applications towards clinical diagnostics. While OGM offers a compelling alternative to long-read sequencing in terms of cost and throughput, Bionano must demonstrate consistent performance and ease of use to achieve widespread adoption and capture a meaningful share of the rapidly evolving cytogenomics market.
What we're watching
- Adoption Rate
- The pace at which Bionano can convert pilot programs and research use into commercially viable, high-volume diagnostic workflows will determine its long-term revenue potential.
- Competitive Landscape
- How Bionano’s cost and scalability advantages against long-read sequencing will hold up as competitors innovate and potentially lower their own costs.
- Software Integration
- The success of OMKar and VIA’s integration with existing laboratory information management systems (LIMS) will be critical for streamlining workflows and driving broader adoption.
Related topics